Clinical trials: Patients With Advanced Solid Tumors
Solid Tumor, Immune Checkpoint Inhibitor
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
This phase I trial evaluates the effects of RX-af01 in combination with toripalimab (PD-1 antibody), in treating patients with refractory advanced solid tumors, including melanoma, nasopharyngeal squamous carcinoma, esophageal…
- Conditions
- Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora
- Trial name
- NCT05576961
- Testing
- RX-af01, Mixed bacteria, High dose RX-af01
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Advanced Cancer
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
The purpose of this study is to determine whether corrected QT (QTc) interval changes occur on an electrocardiogram (ECG) when cetuximab is administered to the study population.
- Trial name
- NCT00698841
- Testing
- Cetuximab
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Solid Tumors
A Study of TYK-00540 in Adult Patients With Solid Tumors
The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.
- Trial name
- ASOTIAPWST (NCT06246071)
- Testing
- TYK-00540
- Where
- China
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- TYK Medicines, Inc
Select Advanced Solid Tumors
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors. Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors.
- Trial name
- NCT06598371
- Testing
- Cyclophosphamide, Fludarabine, KSQ-004EX
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
First-in-Human Study of ICT01 in Patients With Advanced Cancer
Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus…
- Trial name
- EVICTION (NCT04243499)
- Testing
- IV ICT01
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 293 people
- Sponsor
- ImCheck Therapeutics, an Ipsen company
Advanced or Metastatic Solid Tumors
A Phase I Study of TAS-102 in Solid Tumors
The primary objective of this study is to evaluate the pharmacokinetics of TAS-102 after single and multiple dose in Chinese patients with solid tumor.
- Trial name
- NCT02261532
- Testing
- TAS-102
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Cancer, PDAC
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
This study is an investigation to evaluate the safety/tolerability, pharmacokinetics (PK), and efficacy of GFH276 as a single agent in patients with advanced solid tumors harboring RAS mutations.
- Conditions
- Cancer, PDAC, CRC (Colorectal Cancer), NSCLC
- Trial name
- NCT07198321
- Testing
- GFH276
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Neoplasms, Cancer
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor
- Conditions
- Neoplasms, Cancer, Tumors
- Trial name
- NCT01030055
- Testing
- TKI258 (dovitinib)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, NSCLC
Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor
This is a phase Ib single arm, open-label, multiple dose, dose escalating, safety, pharmacokinetic and pharmacodynamic study of the combination of PF-05212384 with paclitaxel and carboplatin.
- Conditions
- Breast Cancer, NSCLC, Ovary Cancer, Endometrial Cancer
- Trial name
- IOSI-NDU-001 (NCT02069158)
- Testing
- PF-05212384, Paclitaxel, Carboplatin
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Cristiana Sessa
Advanced Solid Tumors
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts.
- Trial name
- NCT06384352
- Testing
- YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 500 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumors, Triple Negative Breast Cancer
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
This is a first-in-human, phase I clinical research study with TT-00420, an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple…
- Trial name
- NCT03654547
- Testing
- TT-00420
- Where
- 2 sites in United States, China
- Volunteers
- 48 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
DCSZ11, Solid Tumors
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
To evaluate the safety and efficacy of DCSZ11 in combination with standard therapy in patients with advanced or metastatic solid tumors.
- Conditions
- DCSZ11, Solid Tumors, HNSCC
- Trial name
- NCT07035249
- Testing
- Low Dose DCSZ11, Medium Dose DCSZ11, High Dose DCSZ11
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Neoplasms
First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors
An open-label, non-randomized, Phase I dose-escalation study designed to assess the safety, tolerability, pharmacokinetics(PK) /pharmacodynamics( PD) and tumor response profile of BAY1179470 in subjects with advanced, refractory…
- Trial name
- NCT01881217
- Testing
- BAY1179470
- Where
- 8 sites in Japan, Singapore and 1 more
- Volunteers
- 35 people
- Sponsor
- Bayer
Cancer, Advanced Solid Malignancies
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies.
- Trial name
- NCT01813474
- Testing
- olaparib
- Where
- 3 sites in Japan
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Unspecified Adult Solid Tumor, Protocol Specific
CP-609,754 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CP-609,754 in treating patients who have advanced solid…
- Trial name
- NCT00006085
- Testing
- CP-609,754
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Locally Advanced Solid Tumor
CD8 PET Imaging in Metastatic Solid Tumours
This is a multi-center, single-arm trial designed to evaluate the safety and imaging characteristics of 89Zr-Df-crefmirlimab in patients with locally advanced or metastatic solid tumours prior to and during PD-1 antibody therapy.
- Trial name
- NCT06534190
- Testing
- 89Zr-Df-crefmirlimab PET scan, Nivolumab, Cetrelimab
- Where
- 4 sites in Netherlands, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Solid Tumors
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
The purpose of this study is to determine the safety and maximal tolerated dose of NKP-1339, a ruthenium containing compound administered intravenously on a weekly schedule, in patients with advanced solid tumors.
- Trial name
- NCT01415297
- Testing
- NKP-1339
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Niiki Pharma Inc.
Bladder Cancer, Nerve Sheath Tumor
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody ([89Zr]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid…
- Conditions
- Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies
- Trial name
- NCT07664397
- Testing
- [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robert Flavell, MD, PhD
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
SJG-136 in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with advanced solid tumors. Drugs used in chemotherapy, such as SJG-136, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00103220
- Testing
- SJG-136
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.